AU2017316756A1 - Thiohydantoin androgen receptor antagonists for the treatment of cancer - Google Patents

Thiohydantoin androgen receptor antagonists for the treatment of cancer Download PDF

Info

Publication number
AU2017316756A1
AU2017316756A1 AU2017316756A AU2017316756A AU2017316756A1 AU 2017316756 A1 AU2017316756 A1 AU 2017316756A1 AU 2017316756 A AU2017316756 A AU 2017316756A AU 2017316756 A AU2017316756 A AU 2017316756A AU 2017316756 A1 AU2017316756 A1 AU 2017316756A1
Authority
AU
Australia
Prior art keywords
oxo
octan
thioxo
methyl
trifluoromethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2017316756A
Other languages
English (en)
Inventor
Gilles C. Bignan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of AU2017316756A1 publication Critical patent/AU2017316756A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2017316756A 2016-08-22 2017-08-22 Thiohydantoin androgen receptor antagonists for the treatment of cancer Abandoned AU2017316756A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662377932P 2016-08-22 2016-08-22
US62/377,932 2016-08-22
PCT/IB2017/055063 WO2018037342A1 (en) 2016-08-22 2017-08-22 Thiohydantoin androgen receptor antagonists for the treatment of cancer

Publications (1)

Publication Number Publication Date
AU2017316756A1 true AU2017316756A1 (en) 2019-02-21

Family

ID=60009664

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017316756A Abandoned AU2017316756A1 (en) 2016-08-22 2017-08-22 Thiohydantoin androgen receptor antagonists for the treatment of cancer

Country Status (12)

Country Link
US (1) US20190209539A1 (enExample)
EP (1) EP3500259A1 (enExample)
JP (1) JP2019528290A (enExample)
KR (1) KR20190040030A (enExample)
CN (1) CN109640986A (enExample)
AU (1) AU2017316756A1 (enExample)
BR (1) BR112019003406A2 (enExample)
CA (1) CA3034449A1 (enExample)
MA (1) MA45992A (enExample)
MX (1) MX2019002097A (enExample)
RU (1) RU2019108092A (enExample)
WO (1) WO2018037342A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019029521A1 (zh) * 2017-08-07 2019-02-14 正大天晴药业集团股份有限公司 用作雄激素受体拮抗剂的二芳基硫代乙内酰脲化合物
AU2019387367A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Diarylhydantoin compounds and methods of use thereof
SG11202108300VA (en) 2019-02-01 2021-08-30 Chia Tai Tianqing Pharmaceutical Group Co Ltd Crystal of diarylthiohydantoin compound
CN115403624B (zh) * 2022-09-30 2024-08-27 上海应用技术大学 一种二芳基硫代乙内酰脲化合物及其制备方法与应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3124481B1 (en) * 2010-02-16 2018-03-28 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and uses thereof
EP2911666B1 (en) * 2012-10-26 2022-08-24 Memorial Sloan-Kettering Cancer Center Modulators of resistant androgen receptor

Also Published As

Publication number Publication date
BR112019003406A2 (pt) 2019-05-21
KR20190040030A (ko) 2019-04-16
CN109640986A (zh) 2019-04-16
RU2019108092A3 (enExample) 2020-11-30
MX2019002097A (es) 2019-05-15
US20190209539A1 (en) 2019-07-11
EP3500259A1 (en) 2019-06-26
WO2018037342A1 (en) 2018-03-01
MA45992A (fr) 2019-06-26
JP2019528290A (ja) 2019-10-10
RU2019108092A (ru) 2020-09-22
CA3034449A1 (en) 2018-03-01

Similar Documents

Publication Publication Date Title
EP2646428B1 (en) Heterocyclic derivatives, preparation processes and medical uses thereof
EP2271341B1 (en) Specific inhibitors for vascular endothelial growth factor receptors
EP3584239B1 (en) O-aminoheteroaryl alkynyl-containing compound, preparation method therefor, and use thereof
EP3402791A1 (en) Substituted thiohydantoin derivatives as androgen receptor antagonists
US20190337924A1 (en) Substituted hydantoin and thiohydantoin derivatives as androgen receptor antagonists
EA028035B1 (ru) Производные пиразолопирролидин-4-она и их применение при лечении заболевания
US12595258B2 (en) Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer
EP3500259A1 (en) Thiohydantoin androgen receptor antagonists for the treatment of cancer
EP3481394A1 (en) Thiohydantoin androgen receptor antagonists for the treatment of cancer
US20230000876A1 (en) Treating cancers with a cyclin-dependent kinase inhibitor
WO2008001885A1 (en) Abl KINASE INHIBITOR
EP3878841B1 (en) Indazole kinase inhibitor and use thereof
JP2023500755A (ja) 癌細胞成長抑制効果を示す新規なヘテロ環置換ピリミジン誘導体及びそれを含む薬剤学的組成物
WO2016135140A1 (en) 4-aminoquinazoline derivatives as mth1 inhibitors for the therapy of cancer
RU2789405C2 (ru) Ингибитор киназы pan-kit, имеющий структуру хинолина, и его применение
JP2025502782A (ja) がん治療剤としての強力かつ選択的なｓｍａｒｃａ２分解キメラ分子
CN107849033A (zh) 用于治疗Rac‑GTP酶介导的病症的化合物
HK1172510A (en) Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling
HK1206346A1 (en) N-[4-(quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted